EGFR and lung cancer: The vast majority of lung cancers (>84%) are characterised as nonsmall cell lung cancer (NSCLC) and with 33.7% of these patients identified as having a mutation in the epidermal growth factor receptor (EGFR), which results in constitutive activation of tyrosine kinase activity [1–5].